Keyphrases
Allergy Disease
20%
Attenuation
16%
Attenuation Correction
16%
Clinical Significance
16%
Complete Protection
16%
Dengue
45%
Dengue Vaccine
55%
Dengue Virus
32%
Dengue Virus Serotype 2
19%
DENV-2
19%
Early HIV Infection
16%
Early Humans
16%
Filtered Back Projection
16%
Flavivirus
20%
Fluorodeoxyglucose
16%
Hepatitis A Virus
16%
Highly Active Antiretroviral Therapy (HAART)
50%
Human Challenge Model
19%
Human Immunodeficiency Virus Infection
19%
IL-12 Production
16%
Immune Activation
16%
Immune Response
16%
Immunogenicity
27%
Infectious Diseases
25%
Iterative Reconstruction
16%
Live Attenuated
25%
Live Attenuated Tetravalent
14%
Live Attenuated Tetravalent Dengue Vaccine
38%
Local Inflammation
16%
Neutralizing Antibodies
28%
Non-associated
16%
Placebo
14%
Positron Emission Tomography
16%
Randomized Clinical Trial
16%
Rash
29%
Recombinant
16%
Resting CD4+ T Cells
16%
Second Dose
22%
Skin Rash
16%
Standardized Uptake Value
16%
Tetravalent
30%
Tetravalent Dengue Vaccine
16%
Tetravalent Vaccine
18%
Therapy Modification
16%
TV003
41%
Urine Antibody
16%
Vaccination
23%
Vaccinees
13%
Viremia
23%
Virus Genome
16%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
12%
Aluminum Hydroxide
8%
Atherosclerosis
16%
Clinical Trial
20%
Controlled Clinical Trial
8%
Dengue
58%
Dengue Vaccine
100%
Dengue Virus
31%
Dengue Virus 2
23%
Dengue Virus 3
8%
Dengue Virus 4
20%
Disease
19%
Dosing Studies
16%
Flavivirus
37%
Hepatitis A Virus
16%
HIV
8%
Human Immunodeficiency Virus 1
16%
Human Immunodeficiency Virus Infection
16%
Immunogenicity
29%
Infection
79%
Neutralizing Antibody
36%
Neutropenia
11%
Normal Human
5%
Placebo
44%
Randomized Clinical Trial
16%
Rash
26%
Vaccination Policy
26%
Vaccine
13%
Viremia
37%
Immunology and Microbiology
Antibody Response
20%
Atherosclerosis
16%
Dengue Fever
33%
Dengue Vaccine
66%
Dengue Virus
33%
Dengue Virus 2
26%
Dengue Virus 3
8%
Dengue Virus 4
16%
Dermatitis
5%
Flavivirus
16%
Hepatitis A Virus
16%
Human Immunodeficiency Virus
37%
Human Immunodeficiency Virus 1
39%
Human Immunodeficiency Virus Infection
33%
Immune Response
19%
Immunogenicity
8%
In Situ Hybridization
5%
Infectious Disease
16%
Lymphocyte
5%
Multiple Drug Dose
5%
Neutralizing Antibody
20%
Normal Human
5%
Positron Emission Tomography
16%
Prevalence
8%
Serotype
38%
T Cell
20%
T-Helper Cell
18%
Vaccination Policy
11%
Vaccine Efficacy
31%
Viral Load
19%
Viral Replication
7%
Viremia
41%
Virus Genome
16%
Virus Strain
5%